Lawrence Serfaty, MD, is Professor of Hepatology and Chief of the Liver Diseases Department, Hautepierre Hospital, University of Strasbourg, France. Dr Serfaty received his Medical degree from University of Paris-Sud and completed his Medical training at Saint-Antoine Hospital, Paris. Before moving to Strasbourg University in 2017, he was the Viral and Metabolic Liver Unit Head and Associate Professor of Medicine in the Department of Hepatology at Saint-Antoine Hospital. He is also Associate Researcher in the INSERM UMR_S938, University Pierre&Marie Curie, Paris 6, France.

Dr Serfaty began his research career studying viral HCV in the early 1990s and then focused on potential mechanisms of steatosis and its role in fibrogenesis in chronic HCV. He then extended his field of research to non-alcoholic fatty liver disease (NAFLD), by investigating mechanisms of liver injury associated with insulin resistance in obese patients as well as those with HIV-associated lipodystrophy. He is now focusing his research on global epidemiology and morbi-mortality of NAFLD through the French CONSTANCES cohort, and mechanisms of fibrogenesis in NASH.

Dr Serfaty has been involved in a number of trials evaluating anti-HCV direct-acting antivirals and new molecules in NASH. He has published more than 220 indexed papers. He is a member of the French Association for the Study of the Liver (AFEF) and the European Association for the Study of the Liver (EASL).